Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Gastrointestinal Cancer
- Main trialPhase 1/2
- “This study, the first clinical trial, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of DB-1324.”In the company’s words, NCT07263594 on ClinicalTrials.gov
Other drugs for Gastrointestinal Cancer
- DostarlimabGSK · Phase 3
- CAM2029Camurus AB · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- Disitamab VedotinRemeGen · Phase 3
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
Coming up1
- Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2028 | A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026